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Abstract
Backgrounds: Despite the advances of rheumatoid arthritis (RA) therapeutics, several patients do not receive
adequate treatment due to the toxicity and/or insufficient response of drugs. The aim of this study is to design
photothermally controlled drug release from multifunctional nanoparticles (MNPs) at a near-infrared (NIR) irradiated
site to improve therapeutic efficacy for RA and reduce side effects.
Methods: Au film was deposited onto methotrexate (MTX)-loaded poly(ethylene glycol)-poly(lactic-co-glycolic acid)
(PLGA) nanoparticles, resulting in MTX-loaded MNPs. The synergistic effects of MTX-loaded MNPs with NIR
irradiation were investigated using RA fibroblast-like synoviocytes (FLSs) and collagen-induced arthritis (CIA) mice.
Results: Upon NIR irradiation, NIR resonance of the Au half-shell generated heat locally, accelerating MTX release
from PLGA nanoparticles. In vivo NIR images of MTX-loaded MNPs indicated effective delivery of the MNPs to the
inflamed joints. Moreover, in collagen-induced arthritis mice, MTX-loaded MNPs containing 1/1400 of MTX solution
(repeated-dose administration) had therapeutic effects comparable to conventional treatment with MTX solution. In
vitro experiments showed higher therapeutic efficacy of MTX-loaded MNPs with NIR irradiation than that of
chemotherapy alone.
Conclusions: A combination therapy of MTX-loaded MNP and NIR irradiation showed durable and good treatment
efficacy for the suppression of arthritis in a single administration of small dose of MTX. Our results demonstrate that
the treatment modality using drug-loaded MNP with NIR irradiation may be a promising therapeutic strategy for
the treatment of RA and allow in vivo NIR optical imaging.
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Background
Rheumatoid arthritis (RA) is a chronic inflammatory dis-
ease characterized by synovial hyperplasia and bony ero-
sion, leading to bone destruction and disability [1]. The
mainstay of RA treatment is the administration of
disease-modifying anti-rheumatic drugs (DMARDs)
aimed at improving inflammation and retarding disease
progression [2]. Methotrexate (MTX) is a structural
analogue of folic acid that can competitively inhibit the
binding of dihydrofolic acid to the enzyme dihydrofolate
reductase, consequently inhibiting DNA formation and
cell proliferation. MTX has been widely used as a
DMARD and exhibits excellent efficacy and an accept-
able toxicity profile [3, 4]. However, approximately 30%
of RA patients cannot tolerate MTX because of its side
effects, which include nausea, vomiting, stomatitis, hep-
atotoxicity, and bone marrow suppression [5]. The ad-
verse effects of MTX are dose-dependent, so several
delivery systems using nanoparticles (NPs), liposomes,
microspheres, and different polymers have been sug-
gested to improve the delivery of MTX [6].
Previously, we reported the use of multifunctional
nanoparticles (MNPs) consisting of arginine-glycine-
aspartic acid (RGD)-conjugated MTX-loaded poly(DL-
lactic-co-glycolic acid; PLGA) Au half-shell NPs (RGD-
MTX-PLGA-Au H-S NPs) [7]. RGD binds to a variety of
integrins that are highly expressed in RA synovial tissue,
so it serves as a targeting moiety for inflammatory sites,
leading to enhanced drug delivery into inflamed syno-
vium [8, 9]. However, the use of RGD may hinder clin-
ical applications because of high costs and regulatory
hurdles. Hence, we synthesized MTX-loaded MNPs
without RGD and evaluated their passive targeting and
therapeutic efficacy using a collagen-induced arthritis
(CIA) mouse model. To confirm a synergistic effect of
MTX-loaded MNPs combined with near-infrared (NIR)
irradiation, we also investigated the therapeutic efficacy
of MTX-loaded MNPs combined with NIR irradiation in
RA fibroblast-like synoviocytes (FLSs).
Methods
Materials
PLGA (L:G molar ratio = 50:50; MW= 20,000) was pur-
chased from Wako (Japan). MTX and Pluronic F-127
were purchased from Sigma-Aldrich Chemical Co. (St.
Louis, MO, USA). Thiol-terminated methoxy-
poly(ethylene glycol) (SH-PEG-OCH3, MW= 5000) was
purchased from Creative PEG-Works (USA).
Synthesis and characteristics of MTX-loaded MNPs
The MTX-loaded PLGA NPs were prepared as reported
previously [10, 11]. Briefly, MTX (6 mg, Sigma-Aldrich)
and PLGA (200 mg) were dissolved in dichloroethane
(20 ml), which was stirred for 24 h at room temperature
under nitrogen atmosphere. Then, the organic solution
was slowly added drop-wise into distilled water (200 ml)
containing Pluronic F-127 (2 mg) under magnetic stir-
ring. The NPs were formed immediately, and the solvent
was removed by overnight evaporation at room
temperature. Then, the MTX-loaded PLGA NPs were
collected by centrifugation and re-dispersed in distilled
water (5 ml) by sonication. Au film (15 nm) was depos-
ited onto an MTX-loaded PLGA NP monolayer pre-
pared on a Si substrate using a thermal evaporator. To
stabilize the NPs under in vivo conditions, Au-deposited
MTX-loaded PLGA NPs were released from the sub-
strate surface by sonication into 1 wt% thiol-terminated
methoxy-PEG solutions and then collected by centrifu-
gation, resulting in MTX-loaded MNPs with an Au half-
shell structure (Fig. 1a). The Au half-shell structure of
MTX-loaded MNPs was confirmed using a transmission
electron microscope (TEM) (inset in Fig. 1b). The MTX
loading efficiency, defined as the ratio of the actual mass
of the MTX-loaded MNPs relative to the total mass of
the MTX-unloaded MNPs, was estimated to be approxi-
mately 2.5%. Using dynamic light scattering, the MNPs
were determined to be 100–115 nm in diameter (Add-
itional file 1). The ultraviolet-visible/NIR absorption
spectrum of the MTX-loaded MNPs exhibited a pro-
nounced peak at approximately 810 nm due to the Au
half-shells (Fig. 1b), suggesting that MTX-loaded MNPs
can be used for photothermal treatment and in vivo NIR
absorbance imaging.
Immunofluorescence
Rhodamine-loaded MNPs were synthesized using a pro-
cedure similar to that for the MTX-loaded MNPs. A
total of 200 μl of rhodamine solution was injected into
the two hind foot pad of CIA mice. The same volume of
rhodamine-loaded MNP solution (1 mg/ml dispersed in
phosphate-buffered saline [PBS]) was injected into the
four hind foot pad of other CIA mice. Subsequently, the
limbs of two mice were exposed to NIR at 1.96W/cm2,
while the other two mice were unexposed. The amount
of rhodamine in rhodamine-loaded MNPs was about 1/
1200 of rhodamine solution. One mouse from each
group was sacrificed 1 h after injection, and the other
was sacrificed 24 h after injection. All samples were
counterstained with 4′, 6-diamidino-2-phenylindole
(DAPI). The paws were embedded in OCT compound
and horizontally sectioned.
Biodistribution
MTX-loaded MNPs (200 μl, 1 mg/ml dispersed in PBS)
were administered intravenously (IV) into CIA mice
(total n = 9). The mice were sacrificed 1, 3, or 28 days
after injection (n = 3 at each point), and the major or-
gans (liver, heart, spleen, kidney, and lung) and joints
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were removed from each mouse. Tissue samples were placed
in a mixed acid matrix of aqua regia and heated overnight at
80–90 °C. After additional heating at 130–140 °C for 2 h, the
organic compounds were completely removed and only ion-
ized Au remained. This residue was dissolved in 1ml of 0.5
M HCl and analyzed using an inductively coupled plasma
mass spectrometer (ICP-MS, Agilent 7500C).
Ex vivo NIR imaging
MTX-loaded MNPs (200 μl, 1 mg/ml dispersed in PBS)
were injected intravenously into the CIA mice. The mice
were sacrificed 1, 3, or 28 days after injection, and the
major organs (liver, heart, spleen, kidney, and lung) were
removed from each mouse. NIR absorbance images were
obtained using an eXplore Optix System (Advanced Re-
search Technologies Inc., Montreal, Canada) with the
black color denoting the strongest absorption. Absorbance
at 710~750 nm was detected with a fast photomultiplier
tube (Hamamatsu, Japan) and a time-correlated single
photon counting system (Becker and Hickl GmbH, Berlin,
Germany). All data were calculated using the region-of-
interest function of the analytical workstation software.
Fig. 1 Fabrication and characteristics of MTX-loaded MNPs. a Schematic fabrication process of MTX-loaded MNPs. b TEM images of 100–115-nm
MNPs with Au half-shell (left upper corner) and NIR absorption spectrum of the MTX-loaded MNPs
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CIA induction and assessment
All animal experiments were approved by and conducted
in accordance with the regulations of the Institutional
Animal Care and Use Committee of Yonsei University,
Seoul, Korea. All mice were maintained in a specific
pathogen-free facility. First, an intradermal injection of
200 μg bovine type II collagen (CII, Chondrex, Red-
mond, WA, USA) emulsified in 200 μg of complete
Freund’s adjuvant (Chondrex, Redmond, WA, USA) was
administered in the base of the tail of male DBA/1J mice
(8 weeks old, Central Lab Animal, Inc., Seoul, Korea) to
induce arthritis. Next, a booster intradermal injection of
100 μg bovine CII in incomplete Freund’s was given to
mice at 14 days after the primary immunization. Mice
were monitored twice a week for clinical assessment of
arthritis. Disease severity was assessed in each limb ac-
cording to a previously described scoring system (score
0–4) [12]. The scores for each limb were added, giving a
maximum score of 16 per animal. Arthritis scoring was
performed by two independent observers. Paw thickness
was also measured twice a week with a Vernier caliper.
Upon arthritis development (arthritis score of 8–10), mice
were randomly assigned to each treatment group (n = 5) at
4 weeks after the second booster injection, as described in
Table 1. Briefly, saline (G1, positive control), low-dose MTX
(G3), or PLGA-MNPs (G4–6) were once administered via
intravenous tail injection. MTX-unloaded MNPs were given
to G4, whereas MTX-loaded MNPs were given to G5 and
G6. G4 and G6 were also exposed to 1.96W/cm2 NIR light
for 10min the next day after MNP injection. A high-dose
MTX solution group (G2, representing conventional MTX
treatment) received intraperitoneal injection of 35mg/kg
MTX twice a week, weekly till sacrifice.
Histological examination
Mice were anesthetized and sacrificed on day 28 after
treatment. The front and hind paws (including carpus,
tarsus, and knee joints) were removed, and the skin from
the ends of the digits was removed as well. Samples were
fixed, decalcified, and embedded in paraffin. Tissue sec-
tions were prepared and stained with hematoxylin and
eosin stain. The histological scores for changes in syn-
ovial inflammation, bone erosion, and proliferation were
evaluated as previously described [13]. All histological
analyses were evaluated blindly by three independent
examiners.
Measurement of immunoglobulin G antibodies to type II
collagen and serum cytokines
Serum was collected from animals in each group of mice
and stored at − 70 °C until assayed. The levels of serum
anti-CII immunoglobulin G (IgG) were determined
using a commercially available ELISA kit (#6018, Chon-
drex, Redmond, WA, USA) according to the manufac-
turer’s instructions. Serum levels of inflammatory
murine cytokines interleukin (IL)-6, IL-12p70, and
tumor necrosis factor (TNF)-α were determined using
commercial mouse IL-6, IL-12p70, and TNF-α enzyme-
linked immunosorbent assay (ELISA) kits (BD Biosci-
ences, USA). Each sample was assayed in duplicate.
FLS preparation and culturing
Synovial tissue was obtained from three RA patients
who underwent knee joint replacement surgery at Sever-
ance Hospital, Yonsei University College of Medicine,
Seoul, Korea. The study was approved by the ethics
committee of our institution (IRB No. 4-2019-0683), and
Table 1 Treatments applied to RA-FLS or CIA mice for comparative study of therapeutic efficacy
Group Treated content In vivo Group Treated content In vitro

















































MTX-loaded MNPs 0.2, IV 1.96 Group
6






aTreated volume of MNPs; 30 μl/ml, MNP concentration of 1 mg/ml. bThe arthritic limb was exposed to NIR light for 10 min using a laser diode (λ = 808 nm) 24 h
post-injection. cTreated volume of MNPs; 30 μl/ml, MNP concentration of 1 mg/ml. dThe RA-FLS was exposed to NIR light for 10min using a laser diode (λ = 808
nm) 24 h post-incubation
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written informed consent was obtained from all partici-
pants. All patients satisfied the 1987 revised American
College of Rheumatology classification criteria for RA
[14]. FLS cells were isolated from 3 different donors and
cultured as previously described [15]. Cells obtained
from passages 4 to 8 were seeded onto 12-well plates at
a density of 2 × 104 cells/well in Dulbecco’s modified Ea-
gle’s medium supplemented with 10% fetal bovine serum
(Gibco BRL, Grand Island, NY, USA), 2 mM L-glutam-
ine, 100 units/ml of penicillin, and 100 g/ml of strepto-
mycin. The seeded cells were incubated at 37 °C.
Apoptotic cell assay
A fluorescein isothiocyanate (FITC) Annexin V Apop-
tosis Detection kit (BD Biosciences, San Diego, CA,
USA) was used to quantify the apoptotic cells of cul-
tured FLS, according to the manufacturer’s protocol.
Cells were treated with MTX solution (0.13 or 30 μM),
MTX-unloaded MNPs with or without NIR irradiation,
and MTX-loaded MNPs (0.13 μM of MTX) with or
without NIR irradiation and incubated at 37 °C for 48 h.
NIR irradiation was conducted 24 h after treatment at
0.38W/cm2 for 10 min. Treated cells were harvested by
centrifugation and washed in cold PBS. Annexin V-FITC
and propidium iodide (PI) were added to 400 μl of cells.
Following a 15-min incubation in the dark at room
temperature, the stained cells were immediately analyzed
by flow cytometry (FACS Calibur, BD). A minimum of
10,000 events were collected and analyzed using FlowJo
software (TreeStar, Inc., Ashland, OR, USA). Annexin
V-positive and PI-negative cells were defined as early
apoptotic cells, and PI-positive cells were defined as late
apoptotic or necrotic cells.
Statistical analyses
All statistical analyses were conducted using IBM SPSS
Statistics, version 20 (SPSS Inc., Chicago, IL, USA). Data
are shown as means ± standard deviation. Statistical ana-
lyses of group differences were performed using the
Mann-Whitney U test or ANOVA followed by Tukey’s
method. For all analyses, P values < 0.05 were considered
statistically significant.
Results
Photothermally controlled drug release
To check local photothermal effect on drug release from
MNPs, we injected 200 μl of rhodamine solution into a
CIA mouse and acquired the optical images from the tis-
sues that were sectioned from the inflamed paws at 1 h
and 24 h after injection (Fig. 2 left panel). Rhodamine
was prominently detected at 1 h, but not at 24 h, sug-
gesting that rhodamine was rapidly cleared from the
body. Next, we administered 200 μl of rhodamine-loaded
MNPs (1 mg/ml dispersed in PBS) into the arthritic hind
food pad of CIA mice. Figure 2 shows the optical images
obtained from the inflamed paws unexposed (mid panel)
and exposed to NIR light (right panel) for 10 min at
1.96W/cm2 after treatments of rhodamine-loaded
MNPs, respectively. Both mice showed rhodamine at 24
h, indicating that rhodamine-loaded MNPs were accu-
mulated in the inflamed paw until 24 h. However, com-
pared to the inflamed paw unexposed to NIR, the
inflamed paw exposed to NIR yielded a higher intensity
of rhodamine at 1 and 24 h due to an enhanced release
rate of rhodamine caused by NIR irradiation.
Fig. 2 The local drug release effects of NIR irradiation on MNPs. The sections of the inflamed paw were examined at 1 h and 24 h after local
administration of rhodamine solution and rhodamine-loaded MNPs without/with NIR irradiation. Sections were counterstained by DAPI (blue).
Dotted lines indicate the boundaries of paws. c, connective tissue; ep, epidermis; sm, skeletal muscle. Original magnification × 100
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In vivo delivery and distribution of MNPs
To determine whether MTX-loaded MNPs are delivered
to and accumulated in an inflamed region, 200 μl of
MTX-loaded MNP solution (1 mg/ml dispersed in PBS)
was administrated IV into a CIA mouse with an in-
flamed right paw and non-inflamed left paw. Time-lapse
in vivo NIR absorbance images measured at 24 h after
IV injection revealed that absorbance intensity ≥ 4 × 103
a.u. (blue in Fig. 3a) increased over time in the inflamed
paw whereas a change in the absorbance intensity was
not apparent in the non-inflamed paw (Fig. 3a). These
results indicated that the MTX-loaded MNPs were
preferentially delivered to and accumulated in the in-
flamed paw.
In addition, the distribution of injected MTX-loaded
MNPs (200 μl, 1 mg/ml dispersed in PBS) in major or-
gans and inflamed joint was measured by ICP-MS at 1,
3, and 28 days following the IV injection (Add-
itional file 2a). The MTX-loaded MNPs accumulated ef-
ficiently in the inflamed joint and demonstrated
extended retention until 3 days; 0.16 μg of Au was found
in the inflamed joints of CIA mice treated with MTX-
loaded MNPs 24 h post administration, corresponding to
0.7% of the injected MTX-loaded MNPs. MTX-loaded
Fig. 3 In vivo delivery and distribution of MTX-loaded MNPs. a In vivo NIR absorbance images of inflamed and non-inflamed paws of CIA mouse
after intravenous injection of MTX-loaded MNPs (the picture below is a × 4 magnification of red box). b Thermal images of CIA mice treated with
MTX-loaded MNPs, prior to and post NIR irradiation
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MNPs were also taken up by the liver, lung, and spleen,
with lesser accumulation in the kidney and heart. How-
ever, the amount of MTX-loaded MNPs in these organs
was significantly reduced at 28 days. We also measured
ex vivo NIR absorbance images of the injected MNPs
and found a biodistribution similar to the ICP-MS re-
sults (Additional file 2b).
The left panel of Fig. 3b shows a thermal image of a
CIA mouse treated with 24 h post-injection MTX-
loaded MNPs (200 μl) and unexposed to NIR light. The
temperature was approximately 36 °C throughout the en-
tire body, corresponding to the body temperature of the
mouse. However, when the inflamed paw was irradiated
by NIR (1.96W/cm2) for 10 min, the temperature in-
creased to 43 °C only in the irradiated paw, and no sig-
nificant temperature increase was observed in the region
that was not exposed to NIR (right panel in Fig. 3b).
These findings indicate that heat can be directed to only
the inflamed region using laser guidance.
Comparisons of therapeutic efficacy in CIA mice
To investigate the therapeutic efficacy of MTX-loaded
MNPs, thirty CIA mice were evenly divided into six
groups (n = 5 per group), as summarized in Table 1. The
timetable of CIA induction and applied treatment is de-
scribed in Fig. 4a. Figure 4b shows the clinical index of
these groups as a function of time. For a positive control,
35 mg/kg MTX solution was intraperitoneally adminis-
trated twice per week for 4 weeks, leading to a total
MTX solution of 280 mg/kg (G2). The clinical index de-
creased from day 49, 1 week post treatment. G6 was
treated with MTX-loaded MNPs (0.2 mg/kg of MTX)
and exposed to NIR light (1.96W/cm2) for 10 min at 1
day after MNP treatment. Despite a much lower MTX
dosage for G6 (0.2 mg/kg) than G2 (280 mg/kg), similar
treatment efficacy was obtained. However, when treated
with 0.2 mg/kg MTX solution (G3) or MTX-unloaded
MNPs with NIR irradiation (G4), arthritis was not ame-
liorated in mice although treatment with MTX-loaded
MNPs without NIR irradiation (G5) led to a partial
treatment only during the early period. These results
demonstrate that chemo-photothermal treatment using
MTX-loaded MNPs is a good way to maximize thera-
peutic efficacy and minimize dosage-related MTX side
effects in the treatment of RA. It is well established that
anti-CII antibody is involved in the pathogenesis of CIA
[16]. Serological levels of CII-specific IgG were measured
4 weeks after treatment to determine whether the treat-
ment was associated with a change in the humoral im-
mune response to CII. As shown in Fig. 4c, the anti-CII
IgG levels in the sera of G2-G6 mice were significantly
reduced than those in G1 mice. Among them, the levels
of serum anti-CII IgG decreased the most in G2 and G6.
Histopathological evaluation of the joint sections of
untreated mice showed severe inflammatory cell infiltra-
tion, synovial hyperplasia, and bony erosion. These
histopathological changes were significantly reduced in
G2 and G6 mice. In contrast, no significant differences
were observed in G3, G4, or G5 mice (Fig. 5a, b). To in-
vestigate whether MNPs could decrease serum levels of
pro-inflammatory cytokines, we measured the levels of
IL-6, IL-12p70, and TNF-α in the serum of CIA mice.
Compared with untreated mice, the serum cytokine
levels were significantly decreased in mice treated with
35mg/kg MTX solution twice per week for 4 weeks (G2)
and MTX-loaded MNPs with NIR irradiation (G6)
(Fig. 5c). These results suggest that the therapeutic effect
of MNPs with NIR irradiation is comparable to that of
conventional MTX treatment.
In vitro studies in RA-FLS with MTX-loaded MNPs
To study the anti-arthritic effect of MTX-loaded MNPs
and NIR irradiation in vitro, we divided RA-FLS cells
into seven groups and treated them differently, as sum-
marized in Table 1. G1 was a FLS control group. G2 and
G3 were treated with MTX solution of 0.13 μM and
30 μM, respectively. G4–G7 were prepared by culturing
the cells with MTX-unloaded MNPs (G4 and G5) or
MTX-loaded MNPs (MTX 0.13 μM; G6 and G7) for 1
day, followed by washing with PBS. After that, RA-FLS
cells treated with MNPs were exposed to NIR for 10 min
at 0.38W/cm2 in G5 and G7, and apoptotic cell death
was evaluated using a FACS at 48 h after NIR irradiation
(Fig. 6a). As expected, G2 yielded much less apoptotic
cell death than G3 because of the lower MTX concen-
tration. The apoptotic cell death in G4 tended to be in-
creased than that in G1, but the differences were
insignificant, implying that MTX-unloaded MNPs alone
did not significantly affect apoptotic cell death. Adding
NIR irradiation to MTX-unloaded MNPs (G5) and treat-
ment of MTX-loaded MNPs without NIR irradiation
(G6) significantly enhance apoptotic cell death. The
combined treatment of MTX-loaded MNPs and NIR ir-
radiation (G7) lead the greatest apoptotic cell death, al-
though the dosage of MTX in G7 was only 1/230 of that
in G3. These results demonstrated a synergistic effect of
MTX-loaded MNPs combined with NIR irradiation.
We also measured the cell viability of RA-FLS cells
treated with MTX-unloaded MNPs and exposed to NIR
light for 10 min at different powers to investigate the de-
pendence of cell viability on temperature (Fig. 6b). At
0.82W/cm2, the temperature increased to 60 °C, and the
cell viability was reduced to about 49% due to cell death.
However, for the NIR power less than 0.53W/cm2, the
cell viability remained higher than 88%, indicating that
cell viability was not much affected by NIR irradiation at
low powers.
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Fig. 4 (See legend on next page.)
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Discussion
We investigated the clinical potential of MTX-loaded
MNPs with NIR irradiation for the treatment of RA.
MTX-loaded MNPs showed more delivery to inflamed
joints and induced sustained release, especially when
irradiated with NIR. In vitro and in vivo studies using
RA-FLSs and CIA mice confirmed photothermally con-
trolled drug release and anti-arthritic effects of the com-
bination therapy of MTX-loaded MNPs and NIR
irradiation.
(See figure on previous page.)
Fig. 4 Comparative studies of therapeutic efficacy in CIA mice. a The schedule for CIA induction and treatment. b Severity of arthritis in CIA mice.
NC, negative control; G1, PBS-treated; G2, 35 mg/kg MTX solution twice per week intraperitoneal; G3, 0.2 mg/kg MTX solution once IV; G4, MTX-
unloaded MNPs IV + NIR irradiation; G5, MTX-loaded MNPs IV; G6, MTX-loaded MNPs IV + NIR irradiation. Mean clinical scores were significantly
decreased in G2 and G6 mice compared with untreated mice. c Changes in anti-collagen II IgG titers in mice of different treatment groups. Data
are expressed as mean ± SEM of 5 mice for duplicated serum samples. **P < 0.01, ***P < 0.001 vs. the untreated group (G1)
Fig. 5 MTX-loaded MNPs with NIR irradiation ameliorate histopathologic changes and suppress pro-inflammatory cytokines in CIA mice. a
Histological findings of ankle joints, original magnifications × 100. b, bone; c, cartilage; b, bone erosion; ic, inflammatory cell infiltration; sp,
synovial proliferation. b Semiquantitative analyses of histological changes, *P < 0.01 vs. the untreated group (G1). c Cytokine assays by ELISA. *P <
0.05, **P < 0.01, ***P < 0.001 vs. the untreated group (G1). Values are expressed as mean ± SEM of five mice
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Although MTX is one of the most effective drugs for
the management of RA, some limitations restrict the use
of MTX. The pharmacokinetics of oral low-dose MTX ap-
pears to be variable and largely unpredictable even in pa-
tients with normal renal and hepatic function [17]. MTX
has also several side effects such as gastrointestinal toxic-
ities (stomatitis, nausea, and abdominal distress), alopecia,
bone marrow suppression, and hepatotoxicity [18]. Ap-
proximately one third of RA patients discontinue MTX
due to toxicity rather than lack of efficacy. Hence, there
have been several attempts to develop novel MTX delivery
systems in order to overcome these shortcomings. In this
regard, nano-sized carriers are promising methods which
can selectively deliver therapeutic agents to the inflamma-
tory sites in a controlled or sustained manner [19, 20].
Various nanomaterials including human serum albumin
conjugates, chitosan conjugates, liposomal conjugates, or
in situ forming hydrogels of polymeric micelles have been
suggested [6, 21]. Our polymeric MNPs also showed the
selective delivery to the inflamed site and sustained release
of contained drug and exhibited comparable efficacy in a
small dosage when irradiated with NIR. These aspects of
our MNPs could reduce the concerns about systemic
toxicity of MTX.
Fig. 6 The in vitro effect of MTX-loaded MNPs and NIR irradiation. a Gating strategy (left upper) and representative dot plot images (left lower)
and a graph (right) on induction of apoptotic death by each treatment in RA-FLS. RA-FLS cells were incubated with various treatments for 72 h
and then analyzed by flow cytometry. PBS, PBS-treated FLS; 0.13 μM, MTX solution of 0.13 μM; 30 μM, MTX solution of 30 μM; pMNPs, MTX-
unloaded MNPs; mMNPs, MTX-loaded MNPs; NIR, NIR irradiation. b Cell viability versus temperature during NIR irradiation for RA-FLS cells treated
with MNPs. *P < 0.05, **P < 0.01, ***P < 0.001 vs. the control group. Values are expressed as mean ± SEM of each experiment. The experiments
were conducted in duplicate
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Anti-inflammatory action of low-dose MTX for the
treatment of RA has been related to the induction of
apoptosis in part [22]. Our in vitro studies demonstrated
that apoptotic death in RA-FLSs was induced by MTX-
loaded MNPs and enhanced by NIR irradiation. Because
the dose of MTX within MNPs was 0.13 μM MTX,
MTX-loaded MNPs produced less apoptotic effect, com-
pared with MTX 30 μM. However, when irradiated with
NIR, the apoptotic effect by MTX-loaded MNPs was sig-
nificantly increased. It is well-known that gold (Au) half-
shells strongly absorb NIR light and act as heat carriers
[23]. The cytotoxicity of methotrexate is enhanced by in-
creasing the temperature [24], and another in vitro study
has shown that MTX release from MTX-loaded gold
nanoparticles was temperature-dependent [25]. These
results imply that increased temperature of RA-FLSs
treated with MNPs upon NIR irradiation may enhance
the therapeutic effects of MTX.
In vivo studies using CIA mice revealed that MTX-
loaded MNPs were delivered to the inflamed paw so that
only the inflamed paw could be locally heated using the
NIR laser diode. In addition, MTX-loaded MNPs were
accumulated in the inflamed paw over an extended time
and release of MTX was sustained for at least 3 days.
The characteristics of inflamed RA synovium include
abundant angiogenesis, abnormal and leaky vasculature,
and an influx of inflammatory leukocytes [26]. Because
MTX-loaded MNPs are administrated by the intraven-
ous route, they can be more delivered to the hypervascu-
lar area (passive targeting). Also, the size of our NPs is
attributable to targeted delivery, because 100–115-nm-
sized nanoparticles are not much eliminated by the
spleen and kidney [20]. Another explanation for selective
passive targeting and sustained release of these MNPs
without further integration of a specific targeting moiety
might be due to locally enhanced permeability effects in
the inflamed synovium [27, 28]. In the inflamed joints,
rapid angiogenesis and large gaps between endothelial
cells of blood vessels lead to selective extravasation of
macromolecules. In the normal tissues, macromolecules
are cleared rapidly via the lymphatic system, but the
clearance of macromolecules in the inflammatory inter-
stitium is relatively impaired that they can remain for a
long time. The enhanced permeability effects of PLGA
nanoparticle were previously reported in several studies
[29].
To confirm the local photothermal effect on MNP of
NIR irradiation, body temperatures were measured at
different sites and conditions. Body temperatures were
increased in the MNP-administrated and NIR-irradiated
conditions, and that effect was remarkable in the in-
flamed area. Using rhodamine-loaded MNPs, we showed
prolonged retention for incorporated chemical of MNPs
in the NIR-irradiated areas. Therefore, co-application of
MNP and NIR irradiation showed photothermal effect
and more release of incorporated MTX, leading to better
therapeutic effect in the NIR-irradiated area [30]. Ther-
motherapy is commonly employed means of non-
pharmacological pain management in RA, although its
scientific evidence for efficacy has not been strongly
proven [31]. In addition, mild heating itself has been
shown to decrease the joint stiffness in chronic arthritis
[32]. Markovic et al. also demonstrated that short-term
hyperthermia suppressed the activation of pro-
inflammatory cytokine in RA-FLSs via blocking the acti-
vation of NF-κB [33]. Altogether, the application of NIR
irradiation in patients with RA might be expected not
only to enhance the therapeutic efficacy of administered
MNPs but also to relieve the symptoms associated with
inflammatory arthritis.
Our in vivo studies in the CIA mice model clearly
showed that administration of MNPs with NIR irradi-
ation (1) ameliorated the clinical signs of arthritis, (2)
suppressed serum levels of pro-inflammatory cytokines
and anti-CII IgG, and (3) reduced inflammation and pre-
vent bone erosion in the joints despite the low MTX
dosage. The therapeutic efficacy of the MNPs was simi-
lar to that observed in conventional MTX-treated CIA
mice. Treatment with MTX at the same dosage as load-
ing MTX in the MNPs (G3) did not ameliorate arthritis.
Administration of MNPs without NIR irradiation was
partially effective only during the early period, possibly
because the absence of NIR irradiation hampered the
sustained release of MTX.
Recently, several studies to investigate nanoparticles
containing MTX for the RA treatment have been
published. Reported materials include MTX-lipidic
nanoemulsion, MTX-polysialic acid-trimethyl chitosan
(PSA-TMC) NPs, MTX-superparamagnetic iron oxide
PLGA NPs, N-PSA-TMC NPs coated with decoy oli-
godeoxynucleotides specific to transcription factor
NF-κB, and MTX-loaded biodegradable NPs targeting
CD34+ cells [34–38]. Among them, MTX-lipidic
nanoemulsion was developed for intra-articular use,
and other NPs were relatively complex to make. Un-
like these materials, our MNPs are easy to make and
have Au half-shells for local heating which enable the
photothermal treatment.
Conclusions
In the present study, we demonstrate the synergistic
therapeutic effects of MTX-loaded MNPs and photo-
thermal therapy for the treatment of RA. Combined with
NIR irradiation, these MTX-loaded MNPs exhibited
similar efficacy with a much lower dosage of MTX (ap-
proximately 1/1400) without a targeting ligand. Add-
itionally, repetitive dosing with MTX-containing MNPs
may enhance the therapeutic effect on arthritis; further
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studies will be required to examine these possibilities.
Because of their relatively easy synthesis, low toxicity,
and synergistic effect with NIR irradiation, these MNPs
could have great potential for the treatment of RA. Fur-
thermore, these MNP systems can be applied with other
DMARDs.
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